| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Oracle Health and Life Sciences and Baylor College of Medicine today announced they will collaborate to advance research and clinical insights into alcohol-related liver disease (ALD), one of the fastest-growing causes of liver-related illness and mortality in the United States.
Through this collaboration, Baylor College of Medicine plans to leverage Oracle Health's AI data platform and real-world data (RWD), containing more than 120 million longitudinal anonymized patient records, to establish one of the nation's largest ALD cohorts. Using Oracle Health solutions, Baylor College of Medicine plans to increase its RWD cohort to more than one million patients to support research that is expected to lead to earlier identification of ALD, deepen understanding of disease progression, and ultimately inform more effective prevention and treatment strategies.
"Alcohol-related liver disease represents a critical public health challenge, and earlier identification is key to changing outcomes," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "With Oracle's robust data and analytics capabilities and Baylor's expertise in clinical research and patient care, we have the opportunity to help transform how this condition is studied, diagnosed, and treated."
Baylor College of Medicine researchers plan to use Oracle's comprehensive datasets and research-ready AI agents to uncover patterns, risk factors, and predictive markers of disease progression. The goal is to empower clinicians with actionable insights that can improve patient outcomes while also supporting public health strategies to reduce the burden of ALD nationwide.
Posted In: ORCL
